We also observed that mutations in TP53 and TET2 were not detected in de novo AML but presented in sAML and R/R AML, suggesting that these mutations were likely acquired during disease relapse or progression and may influence treatment response and outcomes. This evidence concerns the gene TP53 and acute myeloid leukemia.